Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
Recruiting · NCT05177133 · Registry updated 2024-08-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms, esophageal adenocarcinoma, gastric adenocarcinoma | Recruiting | Phase 2 | 2024-08-02 | NCT05177133 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 199 |
| Incyte Corporation | 153 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Academic Medical Center, Medical Oncology | Amsterdam | Netherlands | 4 |
| Amsterdam UMC, location VUMC | Amsterdam | Netherlands | 9 |
| Catharina Ziekenhuis | Eindhoven | Netherlands | 43 |
| Erasmus MC | Rotterdam | Netherlands | 57 |
| LUMC | Leiden | Netherlands | 10 |
| Medisch Centrum Leeuwarden | Leeuwarden | Netherlands | 24 |
| Radboud UMC | Nijmegen | Netherlands | 25 |
| UMC Utrecht | Utrecht | Netherlands | 42 |